T-Cell Acute Lymphoblastic Leukemia/Lymphoma
4
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Cd5 Car T Ct125b
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells
Research Network
Common Treatments
- Cd5 Car T Ct125b1
- Allogeneic Anticd7 Cart Cells Beam2011
- Senlt71
- Cd7 Cart1
Active Sponsors
- Hebei Senlang Biotechnology Inc., Ltd.2
- Stephan Grupp MD PhD1
- Beam Therapeutics Inc.1
- Beijing Boren Hospital1
Top Investigators
Beijing Gaobo Boren Hospital
Children's Hospital of Philadelphia